Group 1 - The core point of the article is that Chunli Medical (688236.SH) is currently trading at 22.12 yuan, reflecting a decline of 3.24% and is in a state of breaking its initial public offering price [1] - Chunli Medical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 30, 2021, with an initial offering price of 29.81 yuan and issued a total of 38.428 million shares [1] - The total amount raised during the IPO was 1.145 billion yuan, with a net amount of 1.067 billion yuan after deducting issuance costs, which was 932.8717 million yuan less than the originally planned net fundraising amount [1] Group 2 - The company intended to raise 2 billion yuan for various projects, including orthopedic implants and supporting materials, R&D center construction, marketing network development, and working capital [1] - The total issuance costs amounted to 78.4104 million yuan, with Huatai United Securities receiving a sponsorship fee of 1.5 million yuan and underwriting fees of 65.2359 million yuan [1]

Company Performance - The company's stock price has shown a downward adjustment, with a decline of 3.95% over the past 7 days, and a single-day drop of 3.24% on February 12, closing at 22.12 yuan [1][2] - Despite significant growth in revenue and net profit, with a year-on-year increase of 213.21% in net profit attributable to the parent company, the positive performance has not alleviated short-term negative market sentiment [5] Industry Environment - The National Healthcare Security Administration reported typical cases of commercial bribery in the orthopedic field, revealing kickback ratios as high as 30%-40%, indicating a "golden sales" phenomenon in the industry [3] - Although leading companies, including the company in question, have generally forecasted revenue growth for 2025, there are concerns that regulatory actions may have a long-term impact on sales models and profitability within the industry [3] Market Sentiment - Despite a 16.56% increase in financing balance over the past 5 days, there was a net outflow of 337.38 thousand yuan in main funds on February 12, indicating a net selling state by large investors [4] - The stock has experienced a significant decline of 19.15% over the past 20 days, reflecting cautious market sentiment [4]

Core Viewpoint - The company has successfully achieved mass production of its surgical robots, which integrate advanced intelligent technologies and have received regulatory certifications for various orthopedic procedures [1] Group 1: Product Development - The company has obtained regulatory certifications for hip, knee, and unicompartmental surgical robots, indicating readiness for market deployment [1] - The surgical robots provide a comprehensive digital orthopedic solution covering pre-operative, intra-operative, and post-operative stages [1] Group 2: International Expansion - The company is actively responding to national "Belt and Road" policies and is steadily advancing its international business layout [1]

Core Viewpoint - Spring Medical has experienced a decline in stock price and trading volume, with a notable drop in recent trading days, indicating potential investor concerns about the company's performance and market position [1]. Group 1: Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, is based in Tongzhou District, Beijing, and specializes in the research, production, and sales of implantable orthopedic medical devices [1]. - The company's main products include joint prosthetics (hip, knee, shoulder, elbow) and a full range of spinal implant products [1]. - The revenue composition of the company is predominantly from medical device products at 99.89%, with other sources contributing 0.11% [1]. Group 2: Financial Performance - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, which is a significant increase of 213.21% [2]. - Since its A-share listing, the company has distributed a total of 440 million yuan in dividends, with 390 million yuan distributed over the past three years [3]. Group 3: Market Activity - As of February 12, 2023, Spring Medical's stock price was 22.40 yuan per share, with a market capitalization of 8.592 billion yuan [1]. - The stock has seen a year-to-date decline of 1.20%, a 5-day drop of 3.16%, an 18.13% decrease over the past 20 days, and a 12.98% decline over the last 60 days [1]. - The company has experienced a net outflow of 1.0456 million yuan in principal funds, with large orders accounting for 3.27% of purchases and 8.11% of sales [1].

Group 1 - The core business of the company is focused on the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2] - As of September 30, 2025, the company achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a significant increase of 213.21% [2] - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [3] Group 2 - As of February 10, 2023, the company's financing balance reached 50 million yuan, accounting for 0.75% of its market capitalization, indicating a high level of financing activity [1] - The company had a net financing purchase of 1.46 million yuan on February 10, 2023, with a total financing buy of 4.19 million yuan and repayment of 2.73 million yuan [1] - The company’s stock has seen an increase in shareholder accounts, with a total of 6,164 shareholders as of September 30, 2025, reflecting a 4.12% increase [2]

Core Viewpoint - Southbound funds have reduced their holdings in Spring Medical (01858.HK) by 31,000 shares on February 10, indicating a trend of net selling over recent trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have reduced their holdings on 4 days, with a total net reduction of 789,500 shares [1] - Over the past 20 trading days, there have been 11 days of net selling, resulting in a cumulative net reduction of 901,200 shares [1] - Currently, southbound funds hold 41,446,300 shares of Spring Medical, accounting for 43.55% of the company's total issued ordinary shares [1] Group 2: Company Overview - Beijing Spring Medical Co., Ltd. specializes in the research, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover major human joints such as hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Core Viewpoint - The orthopedic industry is facing scrutiny due to commercial bribery cases, while major companies are reporting significant revenue and profit growth for 2025, highlighting a contrast between industry recovery and ongoing issues of high sales expenses and unethical practices [2][6][8]. Group 1: Bribery Cases and Industry Impact - The National Healthcare Security Administration has reported significant bribery cases in the orthopedic field, with kickback rates reaching up to 40% [2][3]. - In a case involving a hospital director, illegal kickbacks totaled 2.72 million yuan, with a supplier paying 35% of the total supply as a monthly kickback [4]. - Another case revealed a hospital official receiving 3.66 million yuan in bribes over ten years, with kickback rates between 20% and 40% for various orthopedic devices [5]. Group 2: Financial Performance of Companies - Major orthopedic companies like Spring Medical, Dabo Medical, and Kelly Tai are forecasting significant revenue and profit increases for 2025, with some companies expecting profit growth exceeding 300% [2][6][7]. - The orthopedic consumables sector saw a 17% year-on-year revenue growth in the first three quarters of 2025, with net profit increasing by 81% [6][16]. - Spring Medical anticipates a net profit of 245 to 288 million yuan for 2025, representing a year-on-year increase of 96.01% to 130.41% [6][16]. Group 3: Sales Expenses and Challenges - Despite positive financial forecasts, high sales expenses remain a significant concern, with some companies' sales expense ratios exceeding the industry average [8][18]. - For instance, Dabo Medical's sales expense ratio was approximately 26.7%, indicating elevated marketing costs within the orthopedic sector [18]. - The ongoing high sales expenses are squeezing companies' research and development budgets, with reductions in R&D spending reported by several firms [19].

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Spring Medical, indicating a slight decline in stock price and notable financing activities on February 9 [1] - On February 9, Spring Medical's stock price fell by 0.35%, with a trading volume of 34.99 million yuan. The financing buy-in amounted to 5.24 million yuan, while the financing repayment was 3.77 million yuan, resulting in a net financing buy of 1.48 million yuan [1] - As of February 9, the total financing and securities lending balance for Spring Medical reached 48.55 million yuan, with the financing balance accounting for 0.73% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2] - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems. Its products are exported to various regions, including Asia, South America, Africa, Oceania, and Europe [2] - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% [2] Group 3 - Since its A-share listing, Spring Medical has distributed a total of 440 million yuan in dividends, with 390 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders for Spring Medical increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2][3] - Among the top ten circulating shareholders, new entrants include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed A, holding 2.96 million shares and 2.83 million shares, respectively [3]

证券之星消息，截至2026年2月9日收盘，春立医疗(688236)报收于23.0元，下跌0.35%，换手率0.53%， 成交量1.52万手，成交额3498.88万元。 2月9日的资金流向数据方面，主力资金净流出63.27万元，占总成交额1.81%，游资资金净流入391.14万 元，占总成交额11.18%，散户资金净流出327.87万元，占总成交额9.37%。 春立医疗融资融券信息显示，融资方面，当日融资买入524.38万元，融资偿还376.73万元，融资净买入 147.65万元。融券方面，融券卖出400.0股，融券偿还0.0股，融券余量800.0股，融券余额1.84万元。融 资融券余额4854.82万元。 近5日融资融券数据一览见下表： | 日期 | 涨跌幅 | | 融资余额(元) 融资净买入(元) 融券余量(股) | | (品)用品要求量 | 融资融券余额(元) | | --- | --- | --- | --- | --- | --- | --- | | 2026-02-09 | -0.35% | 4852.98万 | 147.65万 | 800.0 | 400.0 | 4854.82万 | | 2026 ...

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 12,700 shares on February 9, indicating a fluctuating interest from these investors in the company [1] Group 1: Southbound Fund Activity - Over the past five trading days, there were three days of net reductions in holdings by southbound funds, totaling a net decrease of 674,000 shares [1] - In the last twenty trading days, there were ten days of net reductions, with a cumulative net decrease of 769,000 shares [1] - Currently, southbound funds hold 41,477,300 shares of Chuangli Medical, accounting for 43.59% of the company's total issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. specializes in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]